List view / Grid view
Featured in this in-depth focus, articles exploring why cleanroom infrastructure must transform to meet the needs of the cell and gene therapy industry and discussing a novel platform for discovering and developing genetically-targeted therapies for autoimmune diseases.
Download this in-depth focus to learn about how the logistics industry rose to the challenge of the COVID-19 vaccine rollout and the complexities of the production process for plasma derived therapies.
This article from the global consulting firm Charles River Associates (CRA) describes how manufacturers must address and overcome three key barriers hindering progress in the microbiome sector and the optimal strategies needed to demonstrate the value of microbiome-based therapies in successful commercialisation.
The lowest dose of the gene therapy was shown to be safe and somewhat improved vision in the first three patients treated in the trial.
![A bottle of Advil over the counter pain medication [Credit: Rajarajan Kannanb/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Advil-bottle-300x278.jpg)
![A bottle of Advil over the counter pain medication [Credit: Rajarajan Kannanb/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Advil-bottle-e1618917106973.jpg)
GSK Consumer Healthcare aims to reduce the plastic in all Advil bottles sold online and in store by 20 percent by 2022.
The Emergency Use Authorization (EUA) was revoked after data suggested that, in the US, the prevalence of variants likely to be resistant to the monoclonal antibody bamlanivimab alone is increasing.
The ChAd63-KH vaccine, used to treat leishmaniasis rather than prevent in this trial, significantly improved symptoms in patients with persistent post-kala-azar dermal leishmaniasis.
Initial results suggest NT-300 (nitazoxanide extended-release tablets, 300mg) reduces progression to severe illness in mild to moderate COVID-19 patients.
Interim Phase I/II trial results show Rocket’s ex vivo lentiviral gene therapy candidate, RP-L201, is safe and of benefit to paediatric patients with severe Leukocyte Adhesion Deficiency-I.
Research suggests the increasing R&D investment in and adoption of biologics will drive growth in the global biologics contract development and manufacturing organisation (CDMO) market.
The trial will evaluate whether the novel IC14 anti-CD14 antibody can reduce recovery time and severity of COVID-19 symptoms in hospitalised patients.
BioVersys will receive €20 million in funding to support its development of new treatments for antimicrobial resistant infections.
A new report suggests the global biotechnology and pharmaceutical services outsourcing market will grow because of the pandemic and rising drug development costs and R&D investments.
A report indicates ongoing demand for COVID-19 vaccines and other biologics, as well as increasing investment will drive a 16.6 percent CAGR in the bioreactors market.
The observatory will collate drug safety data, analyses and decisions into a single source to help pharma identify regional differences in decision-making.
